Stevia Nutra Corp (STNT) 0.0007 $STNT STENTYS E
Post# of 273254
Posted On: 07/26/2016 7:10:19 PM
Stevia Nutra Corp (STNT) 0.0007 $STNT
STENTYS Enrolls First Patient in Left Main Clinical Trial
BusinessWire - Tue Jul 19, 10:46AM CDT
Regulatory News:
STENTYS: Appointment of Cardiolovascular Device Veteran as New CEO
BusinessWire - Mon Jul 04, 11:13AM CDT
--Gonzague Issenmann recruited his successor to ensure the company he has created continues to thrive
STENTYS Announces CE Marking of Its Longest Xposition Stent
BusinessWire - Wed Jun 08, 10:46AM CDT
Regulatory News:
STENTYS Announces the CE Marking of the Self-Apposing Stent for Left Main Coronary Artery Disease
BusinessWire - Mon Mar 21, 1:00AM CDT
Regulatory News:
STENTYS Reports 81% Year-over-Year Growth in Fourth-Quarter 2015 Revenues
BusinessWire - Wed Jan 13, 10:45AM CST
Regulatory News:
STENTYS: Enrollment Completion of MiStent Randomized Trial against Xience
BusinessWire - Wed Dec 09, 10:45AM CST
--Primary endpoint results to be announced in H1 2017
STENTYS Sirolimus-Eluting Stent Confirms Best-in-Class Performance at 3 Years
BusinessWire - Mon Oct 12, 12:09PM CDT
STENTYS (Paris:STNT) (FR0010949404 -- STNT), a medical technology company commercializing the world's first and only Self-Apposing(R) coronary stent, today announces that three-year follow-up imaging data from the STENTYS arm of the APPOSITION IV clinical study confirms the long-term performance of the sirolimus-eluting Self-Apposing stent. The data will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco, CA.
STENTYS Receives CE Mark for Self-Apposing Stent in Lower Limb Artery Disease
BusinessWire - Mon Sep 28, 11:07AM CDT
STENTYS (Paris:STNT)(FR0010949404 -- STNT), a medical technology company commercializing the world's first and only Self-Apposing(R) coronary stent, today announced that the Company's Drug-Eluting stent received CE Mark for treatment of below-the-knee (BTK) arteries, making STENTYS' product the first self-expanding and drug-eluting stent with regulatory approval in Europe for this indication.
STENTYS Reports First Half 2015 Financial Results
BusinessWire - Thu Sep 17, 11:57AM CDT
--Gross margin up 1,400 basis points to 53%
STENTYS Reports 40% Increase in Revenues in Second Quarter of 2015
BusinessWire - Wed Jul 08, 11:16AM CDT
STENTYS (Paris:STNT) (FR0010949404 - STNT), a medical technology company commercializing the world's first and only Self-Apposing(R) coronary stent, today announces its revenues and cash position at June 30, 2015.
STENTYS Reports First Quarter 2015 Revenues Rose 28%
BusinessWire - Thu Apr 16, 11:14AM CDT
STENTYS (Paris:STNT) (FR0010949404 -- STNT), a medical technology company commercializing the world's first and only Self-Apposing(R) coronary stent, today announces revenues for the first quarter of 2015.
STENTYS 2014 Annual Results
BusinessWire - Tue Mar 31, 12:22PM CDT
--Solid cash position of EUR18.6 million allowing the commercial launch of the new product portfolio
STENTYS Expands Benefits of First Drug-Eluting, Self-Expanding Stent to Lower Limb Artery Disease
BusinessWire - Wed Jan 28, 11:25AM CST
STENTYS (Paris:STNT) (FR0010949404 -- STNT), a medical technology company commercializing the world's first and only Self-Apposing(R) coronary stent, today announced that its unique Drug-Eluting and Self-Expanding stent was evaluated in 70 patients suffering from critical limb ischemia (CLI) and prevented foot amputation in 99% of them.
STENTYS' Sirolimus-Eluting Stent Receives CE Marking
BusinessWire - Mon Oct 27, 12:50PM CDT
Regulatory News:
STENTYS Revenues for the First 9 Months of 2014 up 16.9%
BusinessWire - Thu Oct 23, 10:45AM CDT
STENTYS (Paris:STNT) (FR0010949404 -- STNT), a medical technology company commercializing, in Europe, the world's first and only Self-Apposing(R) stent to treat acute myocardial infarction (AMI), today announces revenues for the third-quarter and nine-months ended September 30, 2014.
STENTYS Wins Large Regional Tender in Middle East
BusinessWire - Mon Oct 20, 12:17PM CDT
Regulatory News:
STENTYS Enrolls First Patient in Left Main Clinical Trial
BusinessWire - Tue Jul 19, 10:46AM CDT
Regulatory News:
STENTYS: Appointment of Cardiolovascular Device Veteran as New CEO
BusinessWire - Mon Jul 04, 11:13AM CDT
--Gonzague Issenmann recruited his successor to ensure the company he has created continues to thrive
STENTYS Announces CE Marking of Its Longest Xposition Stent
BusinessWire - Wed Jun 08, 10:46AM CDT
Regulatory News:
STENTYS Announces the CE Marking of the Self-Apposing Stent for Left Main Coronary Artery Disease
BusinessWire - Mon Mar 21, 1:00AM CDT
Regulatory News:
STENTYS Reports 81% Year-over-Year Growth in Fourth-Quarter 2015 Revenues
BusinessWire - Wed Jan 13, 10:45AM CST
Regulatory News:
STENTYS: Enrollment Completion of MiStent Randomized Trial against Xience
BusinessWire - Wed Dec 09, 10:45AM CST
--Primary endpoint results to be announced in H1 2017
STENTYS Sirolimus-Eluting Stent Confirms Best-in-Class Performance at 3 Years
BusinessWire - Mon Oct 12, 12:09PM CDT
STENTYS (Paris:STNT) (FR0010949404 -- STNT), a medical technology company commercializing the world's first and only Self-Apposing(R) coronary stent, today announces that three-year follow-up imaging data from the STENTYS arm of the APPOSITION IV clinical study confirms the long-term performance of the sirolimus-eluting Self-Apposing stent. The data will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco, CA.
STENTYS Receives CE Mark for Self-Apposing Stent in Lower Limb Artery Disease
BusinessWire - Mon Sep 28, 11:07AM CDT
STENTYS (Paris:STNT)(FR0010949404 -- STNT), a medical technology company commercializing the world's first and only Self-Apposing(R) coronary stent, today announced that the Company's Drug-Eluting stent received CE Mark for treatment of below-the-knee (BTK) arteries, making STENTYS' product the first self-expanding and drug-eluting stent with regulatory approval in Europe for this indication.
STENTYS Reports First Half 2015 Financial Results
BusinessWire - Thu Sep 17, 11:57AM CDT
--Gross margin up 1,400 basis points to 53%
STENTYS Reports 40% Increase in Revenues in Second Quarter of 2015
BusinessWire - Wed Jul 08, 11:16AM CDT
STENTYS (Paris:STNT) (FR0010949404 - STNT), a medical technology company commercializing the world's first and only Self-Apposing(R) coronary stent, today announces its revenues and cash position at June 30, 2015.
STENTYS Reports First Quarter 2015 Revenues Rose 28%
BusinessWire - Thu Apr 16, 11:14AM CDT
STENTYS (Paris:STNT) (FR0010949404 -- STNT), a medical technology company commercializing the world's first and only Self-Apposing(R) coronary stent, today announces revenues for the first quarter of 2015.
STENTYS 2014 Annual Results
BusinessWire - Tue Mar 31, 12:22PM CDT
--Solid cash position of EUR18.6 million allowing the commercial launch of the new product portfolio
STENTYS Expands Benefits of First Drug-Eluting, Self-Expanding Stent to Lower Limb Artery Disease
BusinessWire - Wed Jan 28, 11:25AM CST
STENTYS (Paris:STNT) (FR0010949404 -- STNT), a medical technology company commercializing the world's first and only Self-Apposing(R) coronary stent, today announced that its unique Drug-Eluting and Self-Expanding stent was evaluated in 70 patients suffering from critical limb ischemia (CLI) and prevented foot amputation in 99% of them.
STENTYS' Sirolimus-Eluting Stent Receives CE Marking
BusinessWire - Mon Oct 27, 12:50PM CDT
Regulatory News:
STENTYS Revenues for the First 9 Months of 2014 up 16.9%
BusinessWire - Thu Oct 23, 10:45AM CDT
STENTYS (Paris:STNT) (FR0010949404 -- STNT), a medical technology company commercializing, in Europe, the world's first and only Self-Apposing(R) stent to treat acute myocardial infarction (AMI), today announces revenues for the third-quarter and nine-months ended September 30, 2014.
STENTYS Wins Large Regional Tender in Middle East
BusinessWire - Mon Oct 20, 12:17PM CDT
Regulatory News:
(0)
(0)Scroll down for more posts ▼